Dr. Akshay Budhraja
Associate Director
11 years of experienceMedicine Specialist, Pulmonologist
MBBS, MD, Fellowship, MBA
Aakash Healthcare Super Speciality Medical Centre, Dwarka, New Delhi
Book an AppointmentAbout Dr. Akshay Budhraja
Dr. Akshay Budhraja is a well-known pulmonologist with more than 11 years of professional experience. His expertise covers bronchial asthma, COPD, pneumonia, respiratory failure, ILD, pulmonary hypertension, sleep disorders, smoking cessation, tuberculosis, sarcoidosis, and lung cancer. Dr. Budhraja is a respiratory and sleep medicine expert with clinical proficiency in treating critically ill patients and a wide range of respiratory conditions. He successfully performed over 3500 Bronchoscopies, 500 EBUS, and 150 Thoracostomies. He completed his MBBS from Barkatullah Univ. and MD in Tuberculosis & Respiratory Diseases/Medicine from People's Coll. of Medical Sciences & Research Centre. He is also associated with many medical societies, including the Indian Chest Society, India, Indian Medical Association (IMA), the Delhi Medical Council, India (DMC), and the Haryana Medical Council, India(HMC) Dr. Akshay was the principal investigator of 6 International Drug Trials and 3 Ongoing International Drug Trials for COVID-19. He also did various learning programs at the Royal Coll. of Physicians, London.Education
MBBS, Barkatullah Univ., Bhopal, 2013 MD, (Respiratory Medicine), People's Coll. of Medical Sciences & Research Centre, 2016 Fellowship Respiratory & Sleep Medicine, Medanta-The Medicity, Gurgaon, 2018 MBA, (Health Care Administration/Management), Univ. of Virginia Darden School of Business, 2021Training & Certificates
Learning programme by Royal Coll. of Physicians, LondonPast Experience
Attending Consultant, Venkateshwar Hospitals, 2019 Senior Resident, (Pulmonary Medicine) All India Inst. of Medical Sciences, Bhopal, 2017 Senior Resident, LN Medical Coll. Bhopal,2016Awards
Awarded Best publication Presentation in PULMOCON, Ujjain, 2014
Associations/Membership
Indian Chest Society, India Indian Medical Association (IMA) Delhi Medical Council, India (DMC) Haryana Medical Council, India.(HMC) Madhya Pradesh Medical Council, India.(MPMC)
Paper Published
DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
Area of Expertise
- Asthma